Sarcoidosis

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis

Retrieved on: 
Thursday, April 4, 2024
Sarcoidosis, ANI, Disease, Incidence, Education, Patient, African Americans, Research, FSR, CAC, Inflammation, Human, Granuloma, Pharmaceutical industry

BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) https://www.anipharmaceuticals.com/ (Nasdaq : ANIP) is proud to support the Foundation for Sarcoidosis Research’s (FSR) commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month.

Key Points: 
  • BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) https://www.anipharmaceuticals.com/ (Nasdaq : ANIP) is proud to support the Foundation for Sarcoidosis Research’s (FSR) commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month.
  • During the month of April, members of the ANI organization are raising awareness of sarcoidosis by wearing “Say Sarcoidosis” pins offered through FSRs National Awareness Campaign, “Say Sarcoidosis.” In addition, ANI members will also be wearing purple on April 13th in honor of “World Sarcoidosis Awareness Day.”
    According to the FSR, sarcoidosis is a rare inflammatory disease characterized by the formation of granulomas predominately in the lungs and, to a lesser extent, in other organs of the body.
  • “We applaud the Foundation for Sarcoidosis Research’s Awareness Campaign – “Say Sarcoidosis” and their ongoing education and support of people who live with sarcoidosis.
  • “We are grateful for ANI Pharmaceuticals’ commitment to increasing awareness and education about those living with sarcoidosis,” said Mary McGowan, Chief Executive Officer of the FSR.

Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

Retrieved on: 
Wednesday, April 3, 2024
Medical device, Annual report, ARG1, Documentation, Biotechnology, Sarcoidosis, Partnership, Patient, Scientific Research Publishing, USP7, Ethics, SPO, Biomarker, Research, Health care, Conception, Cancer, Messenger, POC, PLN, Biology, Royal, MHRA, Polish, Clinical trial, Safety, MOC, Phase, ARG2, Food, FDA, SMART, CDA, Pharmaceutical industry

We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.

Key Points: 
  • We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
  • In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure's flagship clinical programme.
  • We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK.
  • The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.

26 Patient Volunteer Leaders Attend the Foundation for Sarcoidosis Research Global Sarcoidosis Clinic Alliance Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic

Retrieved on: 
Wednesday, March 27, 2024
Conference, Growth, Sarcoidosis, Face, Learning, Volunteering, Disease, Caregiver, Patient, Knowledge, Pulmonology, Hospital, Research, FSR, Division, Hospital for Special Surgery, Health, Nursing

CHICAGO, March 27, 2024 (GLOBE NEWSWIRE) -- 26 Patient Volunteer Leaders representing 16 states and 17 hospitals joined the Foundation for Sarcoidosis Research (FSR) at the inaugural FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic.

Key Points: 
  • CHICAGO, March 27, 2024 (GLOBE NEWSWIRE) -- 26 Patient Volunteer Leaders representing 16 states and 17 hospitals joined the Foundation for Sarcoidosis Research (FSR) at the inaugural FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic.
  • "We are immensely proud of the success of the FSR-GSCA Volunteer Patient Leadership Training Conference," said Mary McGowan, Chief Executive Officer of FSR.
  • The success of the FSR-GSCA Volunteer Patient Leadership Training would not have been possible without the generous support of Cleveland Clinic.
  • For more information about the Foundation for Sarcoidosis Research Global Sarcoidosis Clinic Alliance, visit www.stopsarcoidosis.org.

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

Retrieved on: 
Friday, March 22, 2024
PET/CT, Contract research organization, Biotechnology, Sarcoidosis, Disease, Patient safety, Patient, Tablet, Spirometry, Messenger, Quality of life, Biology, Royal, Fibrosis, Clinical trial, European, Arrest, Safety, Pharmacokinetics, MOC, Phase, KITE, FDA, FVC, ECG, Granuloma, Pharmaceutical industry

The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.

Key Points: 
  • The world's first administration of the chitotriosidase 1 (CHIT1) inhibitor (or placebo) to patient took place at the Royal Infirmary in Edinburgh.
  • As part of the trial, patients will take a daily fixed dose of 25 mg OATD-01 or placebo tablets for 12 weeks.
  • Patient safety will be monitored regularly through laboratory tests, neurological examinations and ECG and spirometry.
  • The study will involve approximately 20-30 centres in the US, the European Union, Norway and the UK.

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 14, 2024
PDT, Research, Conference, Interest, ATS, Biologics license application, Patient, SAN, Howard University, Knowledge, EAP, ATyr Pharma, EDT, NRP2, American Thoracic Society, Downstream, Investment, Clinical trial, Small RNA, Neuropilin, Myelocyte, Safety, Sarcoidosis, Immune system, FGF2, FGFR4, BLA, Pharmaceutical industry

SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.

Key Points: 
  • SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.
  • Based on current enrollment projections, the Company anticipates completing enrollment in the study in the second quarter of 2024.
  • Interested parties may access the call by registering here in order to obtain a dial in, personalized passcode and webcast information.
  • Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: http://investors.atyrpharma.com/events-and-webcasts .

Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients

Retrieved on: 
Monday, March 11, 2024
African Americans, Conference, Sarcoidosis, Disease, Adrenocorticotropic hormone (medication), Inflammation, Patient, Research, Manuscript, Adrenocorticotropic hormone, Respiratory disease, Therapy, FDA, Food, Pharmaceutical industry

DUBLIN, March 11, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmaceutical company, today announced the publication of findings from a retrospective chart review of Acthar® Gel (repository corticotropin injection) treatment outcomes for African American and non-African American patients with symptomatic sarcoidosis – including treatment patterns, co-medication use, and overall health outcomes.1 This analysis suggested that Acthar Gel treatment was associated with similar improvements in health outcomes, a reduction in symptoms, and reduced co-medication use in both African Americans and non-African Americans with symptomatic sarcoidosis.1 The manuscript was recently published online in Therapeutics & Clinical Risk Management.

Key Points: 
  • DUBLIN, March 11, 2024 /PRNewswire/ -- Mallinckrodt plc , a global specialty pharmaceutical company, today announced the publication of findings from a retrospective chart review of Acthar® Gel (repository corticotropin injection) treatment outcomes for African American and non-African American patients with symptomatic sarcoidosis – including treatment patterns, co-medication use, and overall health outcomes.1 This analysis suggested that Acthar Gel treatment was associated with similar improvements in health outcomes, a reduction in symptoms, and reduced co-medication use in both African Americans and non-African Americans with symptomatic sarcoidosis.1 The manuscript was recently published online in Therapeutics & Clinical Risk Management.
  • "The results of this retrospective medical chart review highlight unmet needs that exist for African American patients with symptomatic sarcoidosis, who are disproportionately affected by the disease, and reinforce Acthar Gel's potential to help improve health outcomes for appropriate patients,"1,4,5 said George Wan, Ph.D., M.P.H., Vice President, Evidence Generation and Data Sciences, Mallinckrodt.
  • "This research reflects Mallinckrodt's commitment to collecting real-world data on the relationship between patient characteristics, treatment patterns, and outcomes to support clinicians' treatment decisions and address disparities in symptomatic sarcoidosis care.
  • "1

Foundation for Sarcoidosis Research Partners to Host 30 Volunteer Patient Leaders at Unique In-Person Training at Cleveland Clinic

Retrieved on: 
Friday, March 1, 2024
Hospital, Cleveland Clinic, Caregiver, FSR, Sarcoidosis, Hope, Patient, Knowledge, Nursing

CHICAGO, March 01, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is honored to host its inaugural in-person training of FSR-GSCA Volunteer Patient Leaders from around the United States at Cleveland Clinic, the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) Founding Member.

Key Points: 
  • CHICAGO, March 01, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) is honored to host its inaugural in-person training of FSR-GSCA Volunteer Patient Leaders from around the United States at Cleveland Clinic, the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) Founding Member.
  • This inaugural in-person training of FSR-GSCA Volunteer Patient Leaders has been structured to empower volunteer patient leaders with the skills, knowledge, and connections necessary to make a meaningful impact in the fight against sarcoidosis.
  • Cleveland Clinic is a proud member of the FSR Global Sarcoidosis Clinic Alliance and is honored to hold this training event in collaboration with FSR.
  • For media inquiries or more information about the FSR-GSCA Patient Volunteer Leaders’ Training Event, please contact [email protected] .

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

Retrieved on: 
Wednesday, February 21, 2024
SAN, Sarcoidosis, Scar, Small RNA, Pi, ATyr Pharma, FDA, Inflammation, Food, Scleroderma, Risk, Myelocyte, Health, Safety, Principal investigator, Expanded access, Neuropilin, Systemic scleroderma, ILD, OLE, Patient, Fibrosis, Clinical trial, EAP, Pharmaceutical industry

SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) --  aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced plans to initiate an Individual Patient Expanded Access Program (EAP) for its lead therapeutic candidate, efzofitimod, for patients with pulmonary sarcoidosis. The Individual Patient EAP is intended to allow access for patients who complete the Phase 3 EFZO-FIT™ study and wish to receive treatment with efzofitimod outside of the clinical trial.

Key Points: 
  • Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis.
  • Company initiating program based on blinded EFZO-FIT™ study investigator and patient participant feedback.
  • The Individual Patient EAP is intended to allow access for patients who complete the Phase 3 EFZO-FIT™ study and wish to receive treatment with efzofitimod outside of the clinical trial.
  • “We are pleased to make efzofitimod available to patients beyond the duration of the EFZO-FIT™ clinical trial through this Individual Patient EAP,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.

Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research

Retrieved on: 
Thursday, February 15, 2024
Drug development, Hospital, Patient, Caregiver, Sarcoidosis, FSR, Management

CHICAGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) proudly announces the promotion of Tricha Shivas to Chief of Staff and Strategy.

Key Points: 
  • CHICAGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) proudly announces the promotion of Tricha Shivas to Chief of Staff and Strategy.
  • Ms. Shivas, who joined FSR in 2021 and has served FSR as the Vice President of Research and Strategic Partnerships and the Chief Strategy Officer, has played a pivotal role in the expansive growth of FSR over the last three years.
  • and caregivers committed to finding a cure and ensuring evidence-based, patient-centric care for those living with sarcoidosis.
  • “Since joining FSR three years ago, Tricha has proven to be an extraordinary leader filled with passion and expertise resulting in significant advancements for FSR,” said Mary McGowan, FSR’s Chief Executive Officer.

Autoimmune Disease and Pregnancy: ISB Study Challenges Prevailing Wisdom, Unveils Nuances

Retrieved on: 
Wednesday, January 31, 2024
Other Health, Research, Consumer, Healthcare Reform, Parenting, Science, Baby, Maternity, COVID-19, Other Science, Health, Diabetes, Public Policy, Government, Multimedia, Multiple sclerosis, Sarcoidosis, ISB, Mother, Health information management, Vasculitis, MD, Preterm birth, Inflammatory bowel disease, Antiphospholipid syndrome, Patient, Rheumatoid arthritis, Spondyloarthropathy, Cohort (statistics), Providence, Lupus, Hypertension, Pregnancy, Autoimmunity, Thought, Risk, Psoriatic arthritis, Psoriasis, Autoimmune disease, Gestational age, Birth control

View the full release here: https://www.businesswire.com/news/home/20240131144327/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240131144327/en/
    In a just-published study in the journal Lancet eClinical Health , researchers at the Institute for Systems Biology (ISB) and Providence showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease.
  • Each type of autoimmune disease is different, each person has their own medical history, and risk may change over the course of pregnancy.
  • This study highlights the importance of taking comorbidities into consideration,” said ISB Associate Professor Jennifer Hadlock, MD , who led the study.
  • “These results can help reshape discussions surrounding autoimmune disease and pregnancy, and bring fresh perspective to a traditionally understudied area in research,” Hadlock said.